Download App

Log in to access Online Inquiry
Company Overview More
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children’s Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
CEO: Evans M.B.A., John M.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

BEAM Beam Therapeutics
36.570+1.380+3.92%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Assets
Current assets
Cash, cash equivalents and short term investments
142.83% 1.22B 222.24% 965.65M 222.24% 965.65M 361.58% 933.41M
-Cash and cash equivalents
205.24% 296.82M 245.31% 559.99M 495.45% 965.65M 343.81% 612.02M
-Short-term investments
127.89% 925.78M 195.02% 405.65M -- -- 399.68% 321.38M
Receivables
-- 0 -- 300M -- -- -- --
-Accounts receivable
-- 0 -- 300M -- -- -- --
Prepaid assets
52.09% 16.88M -14.91% 7.36M -- -- 23.62% 8.02M
Total current assets
140.87% 1.24B 312.88% 1.27B 213.2% 965.65M 351.07% 941.42M
Non current assets
Net PPE
25.85% 199.83M 49.14% 186.98M -- -- 241.35% 174.7M
-Gross PPE
29.65% 219.17M 51.23% 203.06M -- -- 220.07% 188.22M
-Accumulated depreciation
-88.57% -19.33M -80.71% -16.08M -- -- -77.29% -13.52M
Investments and advances
-- -- -- -- -- -- -- 24.54M
Other non current assets
-29.11% 14.09M -19.54% 14.47M -- -- -13.57% 15.89M
Total non current assets
19.73% 213.92M 40.52% 201.45M 254.92% 508.81M 209.25% 215.13M
Total assets
109.65% 1.45B 226.44% 1.47B 226.44% 1.47B 315.62% 1.16B
Liabilities
Current liabilities
Payables
-21.51% 6.27M 18.37% 7.47M -- -- 10.85% 7.28M
-accounts payable
-21.51% 6.27M 18.37% 7.47M -- -- 10.85% 7.28M
Current accrued expenses
445.24% 45.51M 638.21% 49.04M -- -- -13.18% 12.01M
Current debt and capital lease obligation
94.06% 11.7M 55.1% 9.83M -- -- 43.62% 8.72M
-Current debt
9.1% 2.34M 7.98% 2.29M -- -- 29.14% 2.24M
-Current capital lease obligation
140.9% 9.36M 78.76% 7.54M -- -- 49.4% 6.48M
Current deferred liabilities
-- 115.05M -- 86.27M -- -- -- 12.82M
Other current liabilities
-56.99% 33.51M -34.84% 49.16M -- -- 207.86% 54.72M
Current liabilities
114.33% 218.8M 108.56% 213.44M -- -- 113.68% 101.39M
Non current liabilities
Long term debt and capital lease obligation
6.03% 138.44M 36.04% 137.82M -- -- 383.82% 136.72M
-Long term debt
-49.29% 2.4M -43.2% 3.01M -- -- -19.11% 3.6M
-Long term capital lease obligation
8.11% 136.03M 40.41% 134.81M -- -- 459.09% 133.12M
Non current deferred liabilities
-- 225.09M -- 262.3M -- -- -- 36.82M
Other non current liabilities
10.08% 42.01M 1282.44% 34.16M -- -- 1015.6% 27.81M
Total non current liabilities
140.35% 405.54M 318.47% 434.28M -- -- 554.78% 201.35M
Total liabilities
130.54% 624.33M 214.25% 647.72M 214.25% 647.72M 287.13% 302.74M
Shareholders'equity
Share capital
13.13% 698K 19.37% 684K -- -- 34.33% 677K
-common stock
13.13% 698K 19.37% 684K -- -- 34.33% 677K
-Preferred stock
-- 0 -- -- -- -- -- --
Retained earnings
-39.77% -837.49M -93.21% -768.27M -- -- -132.84% -703.57M
Paid-in capital
63.42% 1.67B 148.1% 1.59B -- -- 210.28% 1.56B
Gains losses not affecting retained earnings
-11187.5% -2.71M -455.56% -50K -- -- -53.66% 19K
Total stockholders'equity
96.26% 829.07M 236.67% 826.74M 236.67% 826.74M 326.76% 853.81M
Total equity
96.26% 829.07M 236.67% 826.74M 236.67% 826.74M 326.76% 853.81M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%